BullFrog AI Holdings (BFRG) Net Income towards Common Stockholders (2022 - 2026)
BullFrog AI Holdings' (BFRG) quarterly Net Income towards Common Stockholders came in at -$1.4 million in Q2 2026, up 5.33% on a YoY basis from -$1.3 million in Q2 2025, and up 7.34% quarter-over-quarter from -$1.5 million in Q4 2025.
Analysis
BullFrog AI Holdings (BFRG) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
BullFrog AI Holdings (BFRG) has reported Net Income towards Common Stockholders for 5 consecutive years, with -$1.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Income towards Common Stockholders rose 5.33% year-over-year to -$1.4 million; the trailing twelve-month figure through Jun 2026 stood at -$5.9 million (up 16.07% YoY), and the FY2025 full-year result was -$6.5 million, up 7.68% from the prior year.
- Net Income towards Common Stockholders grew to -$1.4 million in Q2 2026 per BFRG's latest filing, from -$1.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$566740.0 in Q1 2022 and bottomed at -$2.0 million in Q1 2025.
- Historically, Net Income towards Common Stockholders has averaged -$1.4 million across 5 years, with a median of -$1.4 million in 2025.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders tumbled 133.89% in 2023, then grew 15.08% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$695520.0 in 2022, then sank by 86.47% to -$1.3 million in 2023, then sank by 34.39% to -$1.7 million in 2024, then advanced by 15.08% to -$1.5 million in 2025, then grew by 7.34% to -$1.4 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$1.4 million, -$1.5 million, and -$1.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 472.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -13.27 Mn |
| 10 | BullFrog AI Holdings | 9.27 Mn | 2.35 Mn | 106,899.00 | -1.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.37 Mn |
| Dec 31, 2025 | -1.48 Mn |
| Sep 30, 2025 | -1.55 Mn |
| Jun 30, 2025 | -1.45 Mn |
| Mar 31, 2025 | -2.02 Mn |
| Dec 31, 2024 | -1.74 Mn |
| Sep 30, 2024 | -1.76 Mn |
| Jun 30, 2024 | -1.61 Mn |
| Mar 31, 2024 | -1.92 Mn |
| Dec 31, 2023 | -1.30 Mn |
| Sep 30, 2023 | -1.25 Mn |
| Jun 30, 2023 | -1.48 Mn |
| Mar 31, 2023 | -1.33 Mn |
| Dec 31, 2022 | -695,520.00 |
| Sep 30, 2022 | -764,711.00 |
| Jun 30, 2022 | -775,975.00 |
| Mar 31, 2022 | -566,740.00 |